Par Equity is a U.K. venture capital firm created to facilitate
members across the UK. The Institute provides a variety of resources, business information, access to professional advisors, and other benefits for companies doing business in the UK. In 2011, in recognition of his experience and contribution to business, Mr. Burden was awarded the status of Fellowship in the Institute of Directors.
investment in small companies with high growth potential. Founded in 2008, Par Equity’s investment model leverages an established international network of over 100 senior industry executives and experienced venture capital and growth investors for investment throughout the investment lifecycle - from origination of value-oriented investments, through operational challenges and later stage funding, to successful exit.
The principal of Dorset Capital LLC has been active in the Institute of Directors, 116 Pall Mall, London, since 1996. IOD is the UK’s largest and oldest membership organization for directors and professional leaders and consists of a network with over 34,500
James E. Burden has over 40 years of experience in corporate finance, law practice, and business operations and is President and majority owner of Dorset Capital, LLC.
Mr. Burden’s involvement with co-founding, financing and operating companies in the U.S. and United Kingdom commenced in the 1980’s when he was elected an Underwriting Member/Name of Lloyd’s of London. Through his Lloyd’s connections in the City of London, he began working with Small and Medium Enterprises in the U.K.
Dorset is assisting Par Equity, a UK-based venture capital firm, expand to the United States. The first focus area will be investing in digital health Par Equity USA expanding Par Equity, a UK-based venture capital firm founded in 2009, to the United States. The first focus area will be the Par Transatlantic HealthTech Fund I (the “Fund”) investing in digital health technology companies with proprietary products that are, or are close to, generating revenue where transatlantic expansion can accelerate the next stage of their growth. Digital technologies provide new solutions to address the increasing costs of healthcare and develop more cost-effective models of personalized patient medical care. HealthTech includes patient monitoring, wearable medical devices, robotics, diagnostics and imaging, secure data management and genomic screening. The Fund will focus on companies suitable for expansion from the U.K. to the U.S. and companies expanding from the U.S. to the U.K. Transatlantic expansion is a milestone that can trigger a valuation inflection and significant returns to the Fund.
In 2001, Mr. Burden was a founding director of EuroGen Pharmaceuticals Ltd., a U.K. company formed to seek European regulatory approvals of a NASDAQ-listed company’s drug portfolio. He also was a founding director of Gloucestershire Innovation Centre, which was formed to develop and manage incubation facilities in the Bank of England’s Southgate House in the center of Gloucester, England. Partners included St. John’s College Cambridge Innovation Centre, the University of Gloucestershire, and HSBC Bank.
In 2005, he was a founding director of Emiliem, Inc., a Delaware corporation. Emiliem, Inc is a private biotechnology company currently focused on all aspects of the drug discovery and development process. This includes understanding the molecular determinants of target modulation as it relates to the efficacy of therapeutics and to potential adverse drug reactions, and diagnostic markers for rare diseases and the computational aspects of predicting both positive and negative patient outcomes.
Mr. Burden received a B.S. degree from the School of Business Administration, University of California, Berkeley (Haas School of Business), a J.D. degree from the University of California, Hastings College of Law, and did post-J.D. studies at the Graduate School of Law, University of Southern California. He is an active member of the California State Bar, a member of The Faculty Club, University of California, Berkeley, and a Fellow of the Institute of Directors, London.